332 related articles for article (PubMed ID: 26971534)
21. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
She D; Xing Z; Cao D
J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
[TBL] [Abstract][Full Text] [Related]
22. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
24. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study.
Steidl E; Müller M; Müller A; Herrlinger U; Hattingen E
J Neurooncol; 2019 Sep; 144(2):409-417. PubMed ID: 31321614
[TBL] [Abstract][Full Text] [Related]
26. Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
Schmainda KM; Prah MA; Marques H; Kim E; Barboriak DP; Boxerman JL
Neuro Oncol; 2021 Feb; 23(2):314-323. PubMed ID: 32678438
[TBL] [Abstract][Full Text] [Related]
27. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
28. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
29. A comparison of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast MRI with and without contrast agent leakage correction in paediatric brain tumours.
Novak J; Withey SB; Lateef S; MacPherson L; Pinkey B; Peet AC
Br J Radiol; 2019 Feb; 92(1094):20170872. PubMed ID: 30358415
[TBL] [Abstract][Full Text] [Related]
30. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.
Boxerman JL; Schmainda KM; Weisskoff RM
AJNR Am J Neuroradiol; 2006 Apr; 27(4):859-67. PubMed ID: 16611779
[TBL] [Abstract][Full Text] [Related]
31. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
[TBL] [Abstract][Full Text] [Related]
32. Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging.
Cho HR; Hong B; Kim H; Park CK; Park SH; Park S; Choi SH
Oncotarget; 2016 Oct; 7(43):69606-69615. PubMed ID: 27626306
[TBL] [Abstract][Full Text] [Related]
33. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
[TBL] [Abstract][Full Text] [Related]
34. Analysis of three leakage-correction methods for DSC-based measurement of relative cerebral blood volume with respect to heterogeneity in human gliomas.
Kluge A; Lukas M; Toth V; Pyka T; Zimmer C; Preibisch C
Magn Reson Imaging; 2016 May; 34(4):410-21. PubMed ID: 26708034
[TBL] [Abstract][Full Text] [Related]
35. Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI.
Chawla S; Wang S; Mohan S; Nasrallah M; Verma G; Brem S; O'Rourke DM; Wolf RL; Poptani H; Nabavizadeh SA
J Magn Reson Imaging; 2019 Jan; 49(1):184-194. PubMed ID: 29676844
[TBL] [Abstract][Full Text] [Related]
36. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
[TBL] [Abstract][Full Text] [Related]
37. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
[TBL] [Abstract][Full Text] [Related]
39. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
[TBL] [Abstract][Full Text] [Related]
40. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
